Abstract
Nitric oxide (NO) is a potent vasodilator. The inhaled form (iNO) improves outcomes in term infants with persistent pulmonary hypertension of the newborn (PPHN) or bronchopulmonary dysplasia-associated pulmonary hypertension in preterm infants. However, in preterm infants, the risks and benefits of iNO use are controversial. Substantial evidence reveals no significant impact on survival or other morbidities in preterm infants with iNO treatment, independent of indication, timing, or duration of use. Many scientific organizations do not recommend the use of iNO in preterm infants, except in unique clinical circumstances with echocardiographic findings of PPHN in the setting of presumed pulmonary hypoplasia.
Similar content being viewed by others
References
Soraisham AS, Harabor A, Shivananda S, et al. Trends and Variations in the use of inhaled nitric oxide in preterm infants in canadian neonatal intensive care units. Am J Perinatol. 2016;33:715–22.
Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 2011;127:363–9.
Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2017;1:CD000399.
Kumar P, Committee on Fetus, Newborn, American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. Pediatrics. 2014;133:164–70.
Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res. 1997;41:457–63.
Walther FJ, Benders MJ, Leighton JO. Early changes in the neonatal circulatory transition. J Pediatr. 1993;123:625–32.
Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037–99.
Kinsella JP, Steinhorn RH, Krishnan US, et al. Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension. J Pediatr. 2016;170:312–4.
Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics. 2011;128:729–39.
Hasan SU, Potenziano J, Konduri GG, et al. Effect of inhaled nitric oxide on survival without bronchopulmonary dysplasia in preterm infants: a randomized clinical trial. JAMA Pediatr. 2017;171:1081–9.
Mourani PM, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2004;170:1006–13.
Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349:2099–107.
Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med. 2005;353:23–32.
Chandrasekharan P, Lakshminrusimha S, Chowdhury D, et al. Early hypoxic respiratory failure in extreme prematurity: mortality and neurodevelopmental outcomes. Pediatrics. 2020;146:e20193318.
Peliowski A, Finer NN, Etches PC, Tierney AJ, Ryan CA. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr. 1995;126:450–3.
Chock VY, Van Meurs KP, Hintz SR, et al. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am J Perinatol. 2009;26:317–22.
Ahmed MS, Giesinger RE, Ibrahim M, et al. Clinical and echocardiography predictors of response to inhaled nitric oxide in hypoxic preterm neonates. J Paediatr Child Health. 2019;55:753–61.
Carey WA, Weaver AL, Mara KC, Clark RH. Inhaled nitric oxide in extremely premature neonates with respiratory distress syndrome. Pediatrics. 2018;141:e20173108.
Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353:13–22.
Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2017;1:CD000509.
Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systematic review. Pediatrics. 2007;120:1088–99.
Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001;59:5–16.
Peliowski A, Canadian Paediatric Society Fetus, Newborn Committee. Inhaled nitric oxide use in newborns. Paediatr Child Health. 2012;17:95–100.
Manja V, Guyatt G, Lakshminrusimha S, et al. Factors influencing decision making in neonatology: inhaled nitric oxide in preterm infants. J Perinatol. 2019;39:86–94.
Soll RF. Inhaled nitric oxide for preterm infants: what can change our practice? Pediatrics. 2018;141:e20174214.
Shiraishi J, Kusuda S, Cho K, et al. Standardization of nitric oxide inhalation in extremely preterm infants in Japan. Pediatr Int. 2019;61:152–7.
Shah DM, Kluckow M. Early functional echocardiogram and inhaled nitric oxide: usefulness in managing neonates born following extreme preterm premature rupture of membranes (PPROM). J Paediatr Child Health. 2011;47:340–5.
Author information
Authors and Affiliations
Contributions
AS drafted and revised the manuscript; VB reviewed and revised the final manuscript; AL conceptualized the manuscript, drafted, reviewed, and revised the final manuscript. AL is the guarantor for this paper.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Stritzke, A., Bhandari, V. & Lodha, A. Use of Inhaled Nitric Oxide in Preterm Infants: Is There Sufficient Evidence?. Indian J Pediatr 89, 262–266 (2022). https://doi.org/10.1007/s12098-021-03827-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-021-03827-0